We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-8.74%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.37B
AUM Growth
-$222M
Cap. Flow
+$343M
Cap. Flow %
14.48%
Top 10 Hldgs %
48.21%
Holding
122
New
26
Increased
34
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$66.1M
2
BDTX icon
Black Diamond Therapeutics
BDTX
+$51.6M
3
SDGR icon
Schrodinger
SDGR
+$33.9M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$30.5M
5
PYPL icon
PayPal
PYPL
+$26.5M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$37M
2
XNCR icon
Xencor
XNCR
+$18.9M
3
BNTX icon
BioNTech
BNTX
+$15.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$11M
5
BABA icon
Alibaba
BABA
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 69.42%
2 Consumer Discretionary 14.34%
3 Miscellaneous 11.65%
4 Financials 1.8%
5 Technology 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MA icon
26
CALL
Mastercard
MA
$503B
$24.2M 1.02%
+100,000
New +$29.7M
BPMC
27
DELISTED
Blueprint Medicines
BPMC
$23.4M 0.99%
400,000
– –
IOVA icon
28
Iovance Biotherapeutics
IOVA
$4.19B
$22.5M 0.95%
750,000
+250,000
+50% +$6.63M
ATRA icon
29
Atara Biotherapeutics
ATRA
$94.2M
$21.3M 0.9%
100,000
+30,000
+43% +$9.52M
KYNB
30
Kyntra Bio
KYNB
$32.3M
$20.9M 0.88%
24,000
+8,000
+50% +$7.95M
GOSS icon
31
Gossamer Bio
GOSS
$65.4M
$18.4M 0.78%
22,612
+2,500
+12% +$2.61M
RUBY
32
DELISTED
Rubius Therapeutics, Inc
RUBY
$17.3M 0.73%
3,883,791
+1,050,000
+37% +$7.8M
ARWR icon
33
Arrowhead Research
ARWR
$11.4B
$17.3M 0.73%
+600,000
New +$24.2M
BMRN icon
34
CALL
BioMarin Pharmaceuticals
BMRN
$12.9B
$16.9M 0.71%
200,000
+100,000
+100% +$8.62M
BBIO icon
35
BridgeBio Pharma
BBIO
$14.1B
$15.9M 0.67%
550,000
+350,000
+175% +$10.9M
PRNB
36
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$14.8M 0.63%
+250,000
New +$14.6M
AGIO icon
37
Agios Pharmaceuticals
AGIO
$2.01B
$14.2M 0.6%
400,000
-200,000
-33% -$9.24M
HARP
38
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$13.9M 0.59%
120,000
+35,000
+41% +$4.92M
VNET
39
VNET Group
VNET
$1.75B
$13.9M 0.59%
+1,000,000
New +$12.3M
TPTX
40
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$13.4M 0.57%
300,000
– –
BPMC
41
CALL
DELISTED
Blueprint Medicines
BPMC
$11.7M 0.49%
200,000
+100,000
+100% +$6.44M
ASND icon
42
Ascendis Pharma A/S
ASND
$17.4B
$11.3M 0.48%
100,000
– –
UBER icon
43
Uber
UBER
$148B
$11.2M 0.47%
400,000
-100,000
-20% -$3.29M
TCOM icon
44
Trip.com Group
TCOM
$24.6B
$10.9M 0.46%
+465,000
New +$14.5M
AUPH icon
45
Aurinia Pharmaceuticals
AUPH
$2.14B
$10.9M 0.46%
+750,000
New +$13.2M
YMAB
46
DELISTED
Y-mAbs Therapeutics
YMAB
$10.4M 0.44%
400,000
– –
SAGE
47
DELISTED
Sage Therapeutics
SAGE
$10.1M 0.42%
350,000
+200,000
+133% +$11.6M
TGTX icon
48
TG Therapeutics
TGTX
$8.25B
$9.84M 0.42%
1,000,000
+350,000
+54% +$4.42M
ALBO
49
DELISTED
Albireo Pharma Inc
ALBO
$9.63M 0.41%
588,125
+137,925
+31% +$3.03M
SWTX
50
DELISTED
SpringWorks Therapeutics
SWTX
$9.45M 0.4%
350,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2020 Portfolio in Review

As of Q1 2020, Artal Group held 122 positions worth $2.37B, down 8.6% from $2.59B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $343M of net new capital in Q1 2020, opening 26 new positions and adding to 34 existing holdings. Its largest new stake was uniQure: 1,150,000 shares worth $54.6M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 63% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Moderna, an estimated $37M trimmed.

  • Artal Group's largest Q1 2020 buy was uniQure: 1,150,000 shares worth $54.6M.
  • Artal Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020, an estimated $30.5M increase.
  • Artal Group's biggest Q1 2020 reduction was Moderna, cutting an estimated $37M.
  • Artal Group fully exited Xencor in Q1 2020, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 48% of its $2.37B portfolio in Q1 2020.
  • Artal Group opened 26 new positions and closed 19 in Q1 2020.
  • Artal Group's portfolio value fell 8.6% quarter-over-quarter to $2.37B.

Based on Artal Group's 13F filing for Q1 2020, filed 14 May 2020.